Lunit, a prominent player in AI for cancer diagnostics and therapeutics, along with Agilent Technologies Inc., a global leader in life sciences, diagnostics, and applied chemical markets, teamed up to develop AI-based companion diagnostic solutions.
The collaboration will adopt Lunit’s AI technology and Agilent’s expertise in tissue-based companion diagnostics to build advanced solutions that meet the demand of novel and complex biomarker assays in drug development.
The service will promote companion diagnostic (CDx) product development, enhancing the precision as well as accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options.
Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The primary aim will be on adopt Lunit's AI algorithms with Agilent’s state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.
This step will achieve a significant step forward for both companies as they seek to redefine the role of artificial intelligence in precision oncology and translational medicine.
Executive Statement
According to Brandon Suh, CEO of Lunit, by combining Agilent’s global leadership in tissue-based diagnostics with Lunit’s proven AI algorithms, they can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence—ultimately ensuring patients receive the right treatment at the right time.
According to Nina Green, vice president and general manager of Agilent’s Clinical Diagnostics Division at Agilent, Agilent is committed to bringing cutting-edge diagnostic solutions to their pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens their ability to offer the most advanced companion diagnostic solutions available. The collaboration will bring next-generation diagnostic tools that enable the advancement of precision medicine globally.